Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway

Mult Scler. 1996 Jul;1(6):372-5. doi: 10.1177/135245859600100618.


A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of 4.5 and 9.0 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly in patients with relapsing-remittent multiple sclerosis is described. The patients are treated for 6 months followed by a 6 months drug-free period. The primary objective is to determine new disease activity analysed by monthly MRI with gadodiamide (GdDTPA-BMA, Omniscan). The study is conducted at eight centers in Norway and is completed in January 1996.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Contrast Media
  • Double-Blind Method
  • Gadolinium DTPA
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Magnetic Resonance Imaging / methods*
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy*
  • Norway
  • Recombinant Proteins
  • Recurrence
  • Remission Induction / methods


  • Contrast Media
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • gadodiamide
  • Gadolinium DTPA